Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-BC8-DOTA + BEAM + ASCT for High-Risk Lymphoid Malignancies
NCT01921387Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2013
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90-DOTA-BC8 in B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, Hodgkin lymphoma (HL), sponsored by Fred Hutchinson Cancer Center. Started Oct 2013; status: completed.
02
Drugs
yttrium-90-DOTA-BC8
03
Conditions
B-cell non-Hodgkin lymphomaT-cell non-Hodgkin lymphomaHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01921387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01921387.